Welcure Drugs & Pharmaceuticals Intrinsic Value
Welcure Drugs & Pharmaceuticals (WELCURE) median intrinsic value is ₹0.96 from 8 valuation models (range ₹1–₹1), vs current price ₹0.32 — +200.0% upside (Trading Below Calculated Value), margin of safety 66.7%. For current market price and key ratios, visit WELCURE stock live price.
WELCURE Valuation Methods Summary — DCF, Graham Number & P/E
Welcure Drugs & Pharmaceuticals intrinsic value across 8 models vs current price ₹0.32 — upside/downside and value range per method. Browse WELCURE complete financial for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹0.96 | ₹0.77 - ₹1.15 | +200.0% | EPS: ₹3.30, Sector P/E: 22x |
| Book Value Method | asset | ₹0.80 | ₹0.72 - ₹0.88 | +150.0% | Book Value/Share: ₹9.20, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹0.64 | ₹0.58 - ₹0.70 | +100.0% | Revenue/Share: ₹34.82, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹0.64 | ₹0.58 - ₹0.70 | +100.0% | EBITDA: ₹46.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹0.96 | ₹0.86 - ₹1.06 | +200.0% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹0.96 | ₹0.86 - ₹1.06 | +200.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹0.64 | ₹0.58 - ₹0.70 | +100.0% | ROE: 34.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹0.96 | ₹0.86 - ₹1.06 | +200.0% | EPS: ₹3.30, BVPS: ₹9.20 |
WELCURE Intrinsic Value vs Market Price — All Valuation Models
Welcure Drugs & Pharmaceuticals fair value range ₹1–₹1 vs current market price ₹0.32 across 8 valuation models. Compare with Welcure Drugs & Pharmaceutical valuation methods to assess whether the stock is under or overvalued.
WELCURE Intrinsic Value Analysis — Undervalued or Overvalued?
Welcure Drugs & Pharmaceuticals median intrinsic value ₹0.96, current price ₹0.32 — Trading Below Calculated Value by 200.0%, margin of safety 66.7%.
What is the intrinsic value of WELCURE?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Welcure Drugs & Pharmaceuticals (WELCURE) is ₹0.96 (median value). With the current market price of ₹0.32, this represents a +200.0% variance from our estimated fair value.
The valuation range spans from ₹0.64 to ₹0.96, indicating ₹0.64 - ₹0.96.
Is WELCURE undervalued or overvalued?
Based on our multi-method analysis, Welcure Drugs & Pharmaceuticals (WELCURE) appears to be trading below calculated value by approximately 200.0%.
WELCURE Financial Health — Key Ratios vs Industry Benchmarks
Welcure Drugs & Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.48 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 34.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.46x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
WELCURE Cash Flow Quality — Operating & Free Cash Flow
Welcure Drugs & Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-222 Cr | ₹-222 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |